BB-1701
- Generic Name
- BB-1701
- Drug Type
- Biotech
- Background
BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06188559
- Locations
- 🇺🇸
Community Cancer Center South, Indianapolis, Indiana, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸UCLA Center for East-West Medicine, Los Angeles, California, United States
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 208
- Registration Number
- NCT04257110
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou, China
🇨🇳The First Affiliated Hospital of Zhejiang University, Hangzhou, China
🇨🇳Linyi Cancer Hospital, Linyi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath